Related Experiment Video
Updated: Jul 19, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
[Therapy of chronic hepatitis C]
1Service de Gastroentérologie et d'Hépatologie, CHUV, Lausanne. Darius.Moradpour@chuv.ch
Abstract:
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma worldwide. Here, we will briefly review current and evolving therapies for chronic hepatitis C. Standard therapy with pegylated interferon-alpha and ribavirin achieves sustained virologic response rates of up to 40-50% in genotype 1- and about 80% in genotype 2- and 3-infected patients. Comprehensive management of chronic hepatitis C takes into account cofactors of disease progression. Novel antiviral strategies will likely complement existing therapeutic modalities in the near future.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Chronic Pancreatitis II: Collaborative Care
Assessment:
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Retrovirus Life Cycles
Cirrhosis II: Pathophysiology
